Alnylam

Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development. Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.

Amarin UK Limited

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly, committed to reducing cardiovascular risk and making a meaningful impact on patients’ lives.

www.amarincorp.co.uk

Amgen

Astra Zeneca UK Limited

Daiichi Sankyo

www.daiichisankyo.com

Novartis

www.novartis.com

NovoNordisk

www.novonordisk.co.uk

Grants

£1,600

Up to £50,000